RT Journal Article
SR Electronic
T1 A steady trickle-down from metro districts and improving epidemic-parameters characterize the increasing COVID-19 cases in India
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.28.20202978
DO 10.1101/2020.09.28.20202978
A1 Santosh Ansumali
A1 Aloke Kumar
A1 Samarth Agarwal
A1 H. J. Shashank
A1 Meher K. Prakash
YR 2020
UL http://medrxiv.org/content/early/2020/09/29/2020.09.28.20202978.abstract
AB Background By mid-September of 2020, the number of daily new infections in India have crossed 95,000. To facilitate an intuition for the spatio-temporal development of the pandemic and to help resource deployment planning, we analyze and describe how the disease burden almost-predictably shifted from large metropolitan districts to sub-urban districts.Methods We gathered the publicly available granular data from 186 different districts (equivalent of counties) on their COVID-19 infections and deaths during the 15 April to 31 August 2020 period. These districts presented an active case burden of 559,566 and a cumulative 2,715,656 infections as of August 31. The epidemiological data of these districts was fit to a susceptible-asymptomatic-infected-recovered-dead (SAIRD) model and the underlying epidemic parameters for each of these districts during the course of 4 months was estimated. We validated these parameters against known epidemiological characteristic distributions and analyzed them to understand their changes in space-time during the pandemic.Findings The center of the burden of the current-active infections which on May 15 was in the large metro districts with most international access shifted continuously and smoothly shifted towards districts which could be accessed by domestic airports and by trains. A linear trend-analysis showed a continuous improvement in most epidemic parameters consistently across the districts with four categories of accessibility from an international travel perspective-large metro, metro, urban and sub-urban districts. The reproduction numbers improved from 1.77 ± 0.58 on May 15 to 1.07 ± 0.13 on August 31 in large metro districts (p-Value of trend 0.0001053); and from 1.58 ± 0.39 on May 15 to 0.94 ± 0.11 on August 31 in sub-urban districts (p-Value of trend 0.0067). The recovery rate per infected person per day improved from 0.0581 ± 0.009 on May 15 to 0.091 ± 0.010 on August 31 in large metro districts (p-Value of trend 0.26 × 10−12); and from 0.059 ± 0.011 on May 15 to 0.100 ± 0.010 on August 31 in sub-urban districts (p-Value of trend 0.12 × 10−16). The death rate of symptomatic individuals which includes the case-fatality-rate as well as the time from symptoms to death, consistently decreased from 0.0025 ± 0.0014 on May 15 to 0.0013 ± 0.0003 on August 31 in large metro districts (p-Value of trend 0.0010); and from 0.0018 ± 0.0008 on May 15 to 0.0014 ± 0.0003 on August 31 in sub-urban districts (p-Value of trend 0.2789).Interpretation As the daily infections continue to rise at a national level, it is important to notice a ‘local-flattening’ in larger metro districts, and a shift of the pandemic-burden towards smaller sized districts in a clear hierarchical fashion of accessibility from an international travel perspective. The pandemic burden shifting towards remotely accessible regions, with possibly lesser health care facilities, is a call for attention to the re-organization of resources.Funding NoneCompeting Interest StatementThe authors have declared no competing interest.Funding StatementNo funding was receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The work is based on publicly available data. No ethics approval was needed. The authors have no conflicts of interest. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe work is based on publicly available data. The scripts and data will be made accessible upon request.